While the E-cad expression level was higher, and CD-44 and C- Myc levels were lower in DMSO-treated breast cancer cells, TGF-B treatment reduced E-cad levels in both cell lines, and the reduction was insignificant in the mesenchymal-like MDA-MB-231. This evidence concerns the gene TGFB1 and breast carcinoma.